Literature DB >> 9144855

Diagnostic bone scanning in oncology.

A Z Krasnow1, R S Hellman, M E Timins, B D Collier, T Anderson, A T Isitman.   

Abstract

Over the last several decades bone scanning has been used extensively in the evaluation of oncology patients to detect bone involvement. It can provide information about disease location, prognosis, and the effect of therapy. Bone scanning offers the advantages of whole body evaluation and the detection of lesions earlier than other techniques. However, as newer diagnostic tools become available, indications for bone scanning must be revised and the results combined with these other tests in order to provide optimum patient care. Advances in instrumentation and the subsequent improvement in image quality have allowed nuclear medicine physicians to provide more accurate bone scan interpretations. By optimizing image acquisition, it is often possible to determine lesion characteristics, which are more likely to represent malignancy. Knowledge of disease pathophysiology and other specific properties of the patient's primary tumor, along with subsequent correlation of scan abnormalities to patient history, physical examination, previous studies, and other radiological examinations, is essential for determining lesion significance. The differential diagnosis of a scan abnormality should also include consideration of both false normal and abnormal causes. The final interpretation should be clearly communicated to the clinician with appropriate recommendations for further evaluation. Only through careful attention to the patient, the clinician, and appropriate study acquisition parameters will bone scanning maintain its place in the evaluation of oncology patients.

Entities:  

Mesh:

Year:  1997        PMID: 9144855     DOI: 10.1016/s0001-2998(97)80043-8

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  14 in total

1.  Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using (18)F-FDG PET/CT and (99m)Tc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation.

Authors:  Hyo Jung Seo; Yun Jung Choi; Hyun Jeong Kim; Yong Hyu Jeong; Arthur Cho; Jae Hoon Lee; Mijin Yun; Hye Jin Choi; Jong Doo Lee; Won Jun Kang
Journal:  Nucl Med Mol Imaging       Date:  2011-08-05

2.  Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.

Authors:  Naotoshi Ota; Katsuhiko Kato; Shingo Iwano; Shinji Ito; Shinji Abe; Naotoshi Fujita; Keiichi Yamashiro; Seichi Yamamoto; Shinji Naganawa
Journal:  Br J Radiol       Date:  2014-02       Impact factor: 3.039

3.  Is the assessment of the central skeleton sufficient for osseous staging in breast cancer patients? A retrospective approach using bone scans.

Authors:  Julia Krammer; Dorothee Engel; Andreas Schnitzer; Clemens G Kaiser; Dietmar J Dinter; Joachim Brade; Stefan O Schoenberg; Klaus Wasser
Journal:  Skeletal Radiol       Date:  2013-01-04       Impact factor: 2.199

4.  Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer.

Authors:  Holger Schirrmeister; Coskun Arslandemir; Gerhard Glatting; Regine Mayer-Steinacker; Martin Bommer; Karsten Dreinhöfer; Andreas Buck; Martin Hetzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-28       Impact factor: 9.236

5.  Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT.

Authors:  Stefan Krüger; Andreas K Buck; Felix M Mottaghy; Ellen Hasenkamp; Sandra Pauls; Christian Schumann; Thomas Wibmer; Tobias Merk; Vinzenz Hombach; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-06       Impact factor: 9.236

Review 6.  Imaging response to systemic therapy for bone metastases.

Authors:  Tobias Bäuerle; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2009-05-26       Impact factor: 5.315

7.  Advances in drug design of radiometal-based imaging agents for bone disorders.

Authors:  Kazuma Ogawa; Hideo Saji
Journal:  Int J Mol Imaging       Date:  2011-12-15

8.  18F-Labeled NaF PET-CT in Detection of Bone Metastases in Patients With Preoperative Lung Cancer.

Authors:  Liangjun Rao; Zhen Zong; Zhifeng Chen; Xiaoyan Wang; Xinchong Shi; Chang Yi; Xiangsong Zhang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

9.  Hyperphosphatemic Tumoral Calcinosis: A Classical Clinico-Radio-Scintigraphic Presentation.

Authors:  Rimesh Pal; Ashwin Singh Parihar; Sanjay Kumar Bhadada; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2021-03-04

10.  Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy.

Authors:  Johann Schoenberger; Silke Rozeboom; Eva Wirthgen-Beyer; Christoph Eilles
Journal:  BMC Nucl Med       Date:  2004-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.